{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:06:36Z","timestamp":1790197596356,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003481","name":"Hebei Normal University","doi-asserted-by":"publisher","award":["L2024J04"],"award-info":[{"award-number":["L2024J04"]}],"id":[{"id":"10.13039\/501100003481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003481","name":"Hebei Normal University","doi-asserted-by":"publisher","award":["L2024ZD16"],"award-info":[{"award-number":["L2024ZD16"]}],"id":[{"id":"10.13039\/501100003481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbcan.2026.189715","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:46:34Z","timestamp":1789515994000},"page":"189715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting ferroptosis as a new paradigm for overcoming sorafenib resistance in hepatocellular carcinoma"],"prefix":"10.1016","volume":"1881","author":[{"given":"Wenxuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189715_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12020149","article-title":"Precision medicine for hepatocellular carcinoma: clinical perspective","volume":"12","author":"Galun","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/JHC.S285726","article-title":"Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions","volume":"8","author":"Fornari","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.bbcan.2026.189715_bb0015","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189715_bb0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116074","article-title":"From synergy to resistance: navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma","volume":"170","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189715_bb0030","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad Spectrum Oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189310","article-title":"Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma","volume":"1880","author":"Zhang","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.110.175786","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"337","author":"Chen","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbcan.2026.189715_bb0045","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neo.2014.06.005","article-title":"SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1\/SHP-1 activation in hepatocellular carcinoma","volume":"16","author":"Su","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189715_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12964-019-0430-7","article-title":"Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1\u2013mediated inhibition of STAT3 and Akt\/VEGFR2 pathway in hepatocellular carcinoma","volume":"17","author":"Saraswati","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189715_bb0055","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cellsig.2014.01.026","article-title":"Upregulation of HIF-2\u03b1 induced by sorafenib contributes to the resistance by activating the TGF-\u03b1\/EGFR pathway in hepatocellular carcinoma cells","volume":"26","author":"Zhao","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbcan.2026.189715_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185088","article-title":"Activation of phosphatidylinositol 3-kinase\/AKT\/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells","volume":"12","author":"Dong","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189715_bb0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","article-title":"Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth","volume":"329","author":"Van Malenstein","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189715_bb0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1159\/000485285","article-title":"Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma","volume":"44","author":"Sun","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bbcan.2026.189715_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","article-title":"Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma","volume":"13","author":"Zhai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189715_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189715_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189566","article-title":"Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms","volume":"1881","author":"Che","year":"2026","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0095","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12935-024-03559-z","article-title":"Ferroptosis: insight into the treatment of hepatocellular carcinoma","volume":"24","author":"Liao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189715_bb0100","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189715_bb0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","article-title":"Decoding ferroptosis for cancer therapy","volume":"25","author":"Wahida","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-026-01128-z","article-title":"Translating ferroptosis into oncology: challenges, opportunities and future directions","volume":"23","author":"Kang","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: more ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","article-title":"Mechanisms controlling cellular and systemic iron homeostasis","volume":"25","author":"Galy","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12915-025-02378-6","article-title":"Iron metabolism and ferroptosis in human health and disease","volume":"23","author":"Zhong","year":"2025","journal-title":"BMC Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0130","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/15548627.2026.2656779","article-title":"NCOA4-mediated ferritinophagy: emerging role and novel therapeutic target in precision oncology","volume":"22","author":"Chen","year":"2026","journal-title":"Autophagy"},{"key":"10.1016\/j.bbcan.2026.189715_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4302","article-title":"Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5","volume":"7","author":"Terzi","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189715_bb0140","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nature24637","article-title":"NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis","volume":"551","author":"Alvarez","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189715_bb0145","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1021\/acschembio.5b00245","article-title":"Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death","volume":"10","author":"Dixon","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nchembio.2238","article-title":"Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis","volume":"13","author":"Kagan","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189715_bb0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189715_bb0165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189715_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","article-title":"GTP Cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid Remodeling","volume":"6","author":"Kraft","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2018.06.013","article-title":"Canonical and non-canonical mechanisms of Nrf2 activation","volume":"134","author":"Silva-Islas","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189715_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101107","article-title":"NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis","volume":"23","author":"Dodson","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.28251","article-title":"Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells","volume":"63","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbcan.2026.189715_bb0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28574","article-title":"Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis","volume":"64","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbcan.2026.189715_bb0200","article-title":"PIP5K1A suppresses ferroptosis and induces sorafenib resistance by stabilizing NRF2 in hepatocellular carcinoma","volume":"12","author":"Guo","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2026.189715_bb0205","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41419-024-06977-z","article-title":"DDX5 deficiency drives non-canonical NF-\u03baB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0210","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41419-021-03718-4","article-title":"GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2\/GPX4 axis","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41419-023-05558-w","article-title":"SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase","volume":"14","author":"Xu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101942","article-title":"Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation","volume":"41","author":"Sun","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0225","article-title":"FNDC5 causes resistance to sorafenib by activating the PI3K\/Akt\/Nrf2 pathway in hepatocellular carcinoma cells","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0230","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/s41467-023-41852-z","article-title":"URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers","volume":"14","author":"Ding","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189715_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02208-x","article-title":"Epigenetic regulation of ferroptosis via ETS1\/miR-23a-3p\/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma","volume":"41","author":"Lu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1464852","article-title":"Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0245","article-title":"In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-\u03b3-induced ferroptosis of hepatocellular carcinoma","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189715_bb0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.freeradbiomed.2023.03.013","article-title":"SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma","volume":"201","author":"Li","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0255","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.7150\/thno.99197","article-title":"Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189715_bb0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-024-02224-3","article-title":"CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p\/SLC7A11 axis","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02567-z","article-title":"Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0275","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0280","article-title":"STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma","volume":"11","author":"Ren","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0285","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.62347\/SUTJ3506","article-title":"STOML2 inhibits sorafenib-induced ferroptosis in hepatocellular carcinoma via p-AKT signaling pathway","volume":"15","author":"Yin","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05448-7","article-title":"PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101181","article-title":"5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1\/SLC7A11-mediated ferroptosis","volume":"78","author":"Shi","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189715_bb0300","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41698-025-01004-6","article-title":"Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis","volume":"9","author":"Lu","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1300","article-title":"Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation","volume":"13","author":"Shi","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0310","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.neo.2021.11.002","article-title":"ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma","volume":"23","author":"Huang","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189715_bb0315","article-title":"SHP-1\/STAT3-Signaling-Axis-regulated coupling between BECN1 and SLC7A11 contributes to sorafenib-induced ferroptosis in hepatocellular carcinoma","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-021-01466-9","article-title":"CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma","volume":"21","author":"Chen","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06302-0","article-title":"RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt\/\u03b2-catenin-ferroptosis axis","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0330","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03061-4","article-title":"PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1\/miR-195-5p axis-dependent manner in hepatocellular carcinoma","volume":"43","author":"Li","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41420-025-02473-1","article-title":"NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis","volume":"11","author":"Gao","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189715_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116251","article-title":"DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma","volume":"225","author":"Li","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0345","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0225","article-title":"Hsa_piR_016975 is a novel target of nanotherapy that boosts hepatoma progression and sorafenib resistance by abating Maspin\/GPX4-mediated ferroptosis","volume":"29","author":"Feng","year":"2025","journal-title":"Biomater. Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102063","article-title":"A CRISPR-Cas9 library screening identifies CARM1 as a critical inhibitor of ferroptosis in hepatocellular carcinoma cells","volume":"34","author":"Cheng","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2026.189715_bb0355","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.freeradbiomed.2023.12.034","article-title":"Interventing mitochondrial PD-L1 suppressed IFN-\u03b3-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis","volume":"212","author":"Li","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115557","article-title":"Identification of ferroptosis-related genes as diagnostic biomarkers and therapeutic targets in sorafenib-resistant HCC via machine learning and experimental validation","volume":"166","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0365","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/15548627.2019.1709762","article-title":"The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target","volume":"16","author":"Xue","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.bbcan.2026.189715_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103786","article-title":"ATF7IP inhibits sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein","volume":"85","author":"Su","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107490","article-title":"GSTA1\/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma","volume":"210","author":"Ma","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0380","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.7150\/thno.59092","article-title":"Targeting iron metabolism in cancer therapy","volume":"11","author":"Morales","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189715_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101052","article-title":"Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma","volume":"73","author":"Hao","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189715_bb0390","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jare.2024.08.021","article-title":"Matrix stiffness-dependent PD-L2 deficiency improves SMYD3\/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC","volume":"73","author":"Wang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0395","doi-asserted-by":"crossref","first-page":"22240","DOI":"10.1021\/acsnano.3c01199","article-title":"Long noncoding RNA URB1-antisense RNA 1 (AS1) suppresses sorafenib-induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2026.189715_bb0400","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41419-025-07772-0","article-title":"Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis","volume":"16","author":"Ye","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111656","article-title":"SCARA5 deficiency inhibits ferroptosis via regulating iron homeostasis and results in sorafenib resistance in hepatocellular carcinoma","volume":"129","author":"Chen","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbcan.2026.189715_bb0410","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13046-024-03169-7","article-title":"CCT3\/ACTN4\/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis","volume":"43","author":"Zhu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0415","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/cas.16186","article-title":"EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2","volume":"115","author":"Lai","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0420","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.7150\/ijbs.105446","article-title":"Mitochondrial regulation of ferroptosis in Cancer cells","volume":"21","author":"Ding","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0425","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12967-024-05404-3","article-title":"Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma","volume":"22","author":"Hu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0430","article-title":"COPS5 triggers ferroptosis defense by stabilizing MK2 in hepatocellular carcinoma","volume":"12","author":"Luo","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2026.189715_bb0435","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41419-024-06789-1","article-title":"Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0440","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/s41467-021-27452-9","article-title":"A targetable LIFR-NF-\u03baB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis","volume":"12","author":"Yao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189715_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101246","article-title":"MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance","volume":"81","author":"Xu","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189715_bb0450","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.7150\/jca.76618","article-title":"Combination of metformin and sorafenib induces ferroptosis of hepatocellular carcinoma through p62-Keap1-Nrf2 pathway","volume":"13","author":"Tang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189715_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158083","article-title":"Metformin enhances the anti-cancer efficacy of sorafenib via suppressing MAPK\/ERK\/Stat3 axis in hepatocellular carcinoma","volume":"23","author":"Siddharth","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0460","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10753-023-01823-4","article-title":"Camptothecin sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via suppression of Nrf2","volume":"46","author":"Elkateb","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.bbcan.2026.189715_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176110","article-title":"Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram\/copper-induced oxidative stress and ferroptosis in renal cell carcinoma","volume":"960","author":"Ni","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0470","article-title":"Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65056-9","article-title":"Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma","volume":"16","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189715_bb0480","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189715_bb0485","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1007\/s10495-024-01997-8","article-title":"Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospects","volume":"29","author":"Lu","year":"2024","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbcan.2026.189715_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216935","article-title":"CRISPR\/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma","volume":"593","author":"Yao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189715_bb0495","article-title":"Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189715_bb0500","article-title":"PGAM1 inhibition promotes HCC ferroptosis and synergizes with anti-PD-1 immunotherapy","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2026.189715_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102463","article-title":"Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing","volume":"56","author":"Hao","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0510","article-title":"Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1\/L1 response","volume":"10","author":"Tang","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2026.189715_bb0515","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT210","article-title":"Phase Ib\/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract]","volume":"84","author":"Iyer","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189715_bb0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41389-026-00630-4","article-title":"Tipping the balance: NRF2's dual role in ferroptotic fate","volume":"15","author":"De Souza","year":"2026","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbcan.2026.189715_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166788","article-title":"Targeting Nrf2 for ferroptosis-based therapy: implications for overcoming ferroptosis evasion and therapy resistance in cancer","volume":"1869","author":"Lee","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.bbcan.2026.189715_bb0530","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-025-01145-0","article-title":"Thirty years of NRF2: advances and therapeutic challenges","volume":"24","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189715_bb0535","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13578-019-0309-8","article-title":"Brusatol, an NRF2 inhibitor for future cancer therapeutic","volume":"9","author":"Cai","year":"2019","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbcan.2026.189715_bb0540","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/mc.22609","article-title":"Brusatol overcomes chemoresistance through inhibition of protein translation","volume":"56","author":"Harder","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbcan.2026.189715_bb0545","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC Tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0550","doi-asserted-by":"crossref","DOI":"10.1177\/09603271221149663","article-title":"Mitochondrial ROS induced by ML385, an Nrf2 inhibitor aggravates the ferroptosis induced by RSL3 in human lung epithelial BEAS-2B cells","volume":"42","author":"Taufani","year":"2023","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0555","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0560","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.tem.2024.09.003","article-title":"Targeting ACSLs to modulate ferroptosis and cancer immunity","volume":"36","author":"Lin","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2026.189715_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1594419","article-title":"ACSL4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0570","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-024-01564-3","article-title":"Ferroptosis: principles and significance in health and disease","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0575","article-title":"Characteristics and biomarkers of ferroptosis","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0580","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5483\/BMBRep.2022.55.11.089","article-title":"DN200434, an orally available inverse agonist of estrogen-related receptor \u03b3, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma","volume":"55","author":"Kim","year":"2022","journal-title":"BMB Rep."},{"key":"10.1016\/j.bbcan.2026.189715_bb0585","doi-asserted-by":"crossref","first-page":"29804","DOI":"10.1021\/acsnano.4c09500","article-title":"Intracellular magnetic hyperthermia sensitizes sorafenib to orthotopic hepatocellular carcinoma via amplified ferroptosis","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2026.189715_bb0590","article-title":"ACSL4 as a context-dependent metabolic switch in hepatocellular carcinoma: implications for ferroptosis and immunotherapy","volume":"17","author":"Luo","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189715_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18132106","article-title":"Hepatic stellate cells antagonize sorafenib-induced ferroptosis in hepatocellular carcinoma by upregulating the LINC00152\/HSPB1 axis","volume":"18","author":"Li","year":"2026","journal-title":"Cancers (Basel)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:42:39Z","timestamp":1790196159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0304419X26001873"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189715","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ferroptosis as a new paradigm for overcoming sorafenib resistance in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189715"}}